122 related articles for article (PubMed ID: 35724381)
21. How Medicare could get better prices on prescription drugs.
Outterson K; Kesselheim AS
Health Aff (Millwood); 2009; 28(5):w832-41. PubMed ID: 19643778
[TBL] [Abstract][Full Text] [Related]
22. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
Sacks CA; Lee CC; Kesselheim AS; Avorn J
JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
[TBL] [Abstract][Full Text] [Related]
23. Online Tools to Decrease Out-of-Pocket Prescription Costs for Patients: A Practical Guide for Urologists.
Pockros B; Cortese BD; Michel K; Ellis TA; Talwar R
Urol Pract; 2024 May; 11(3):454-460. PubMed ID: 38640418
[TBL] [Abstract][Full Text] [Related]
24. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.
Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J
Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619
[TBL] [Abstract][Full Text] [Related]
25. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
Socal MP; Bai G; Anderson GF
JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
[TBL] [Abstract][Full Text] [Related]
26. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
Sheingold S; Nguyen NX
Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
[TBL] [Abstract][Full Text] [Related]
27. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.
Egilman AC; Wallach JD; Ross JS; Dhruva SS
JAMA Intern Med; 2018 Apr; 178(4):567-569. PubMed ID: 29340562
[TBL] [Abstract][Full Text] [Related]
28. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
Song H; Adamson A; Mostaghimi A
JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
[TBL] [Abstract][Full Text] [Related]
29. Recommendations for Lowering Prescription Drug Spending in Public Programs.
Jazowski SA; Dusetzina SB
Ann Intern Med; 2019 Dec; 171(11):855-856. PubMed ID: 31711129
[No Abstract] [Full Text] [Related]
30. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
Socal MP; Bai G; Anderson GF
JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
[TBL] [Abstract][Full Text] [Related]
31. Save green, go generic: be prepared to answer the $4 question.
Hansen D
S D Med; 2009 Nov; 62(11):436-7. PubMed ID: 20128174
[No Abstract] [Full Text] [Related]
32. Medicare Part D: Patients Bear The Cost Of 'Me Too' Brand-Name Drugs.
Gastala NM; Wingrove P; Gaglioti A; Petterson S; Bazemore A
Health Aff (Millwood); 2016 Jul; 35(7):1237-40. PubMed ID: 27385239
[TBL] [Abstract][Full Text] [Related]
33. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization.
Duggan M; Morton FS
Am Econ Rev; 2010 Mar; 100(1):590-607. PubMed ID: 29508975
[No Abstract] [Full Text] [Related]
34. Pharmaceuticals and medical devices: Medicare Part D.
; Steiner DJ
Issue Brief Health Policy Track Serv; 2014 Dec; ():1-31. PubMed ID: 25771554
[No Abstract] [Full Text] [Related]
35. Comparison of Spending on Common Generic Drugs by Medicare vs Costco Members.
Trish E; Gascue L; Ribero R; Van Nuys K; Joyce G
JAMA Intern Med; 2021 Oct; 181(10):1414-1416. PubMed ID: 34228050
[TBL] [Abstract][Full Text] [Related]
36. Effect of Medicare Part D and insurance type on Medicare beneficiary access to prescription medication and use of prescription cost-saving measures.
Urmie JM; Farris KB; Doucette WR; Goedken AM
J Am Pharm Assoc (2003); 2011; 51(1):72-81. PubMed ID: 21247829
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceuticals and medical devices: cost savings.
Chaps NA
Issue Brief Health Policy Track Serv; 2009 Jan; ():1-20. PubMed ID: 19297717
[No Abstract] [Full Text] [Related]
38. Big savings with new generic drugs.
Consum Rep; 2014 May; 79(5):12. PubMed ID: 24724211
[No Abstract] [Full Text] [Related]
39. Broken Promises - How Medicare Part D Has Failed to Deliver Savings to Older Adults.
Dusetzina SB; Muluneh B; Keating NL; Huskamp HA
N Engl J Med; 2020 Dec; 383(24):2299-2301. PubMed ID: 33283988
[No Abstract] [Full Text] [Related]
40. Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model.
Narendrula A; Lang J; Mossialos E
Front Pharmacol; 2023; 14():1179253. PubMed ID: 37727389
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
